Clinical Trials Browser

Phase 1/2 × avapritinib × 90 days × Clear all

NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Phase 1/2 Completed

Glioma, Recurrence, Central Nervous System Neoplasms